ALLMedicine™ Hypertriglyceridemia Center
Research & Reviews 2,311 results
https://doi.org/10.1017/S0007114523000570
The British Journal of Nutrition; Yazdanpanah Z, Salehi-Abargouei A et. al.
Mar 18th, 2023 - Several studies have examined the association between CD36 rs1761667 polymorphism with cardiometabolic risk factors and metabolic syndrome (MetS). This study aimed to investigate the interactions between rs1761667 polymorphism and dietary patterns...
https://doi.org/10.1159/000528574
Blood Purification; Abramovitz BW, Oguntuwase E et. al.
Mar 13th, 2023 - Hypertriglyceridemia is a rarely reported cause of early continuous renal replacement therapy (CRRT) circuit clotting. We have identified and will present 11 published cases in the literature where hypertriglyceridemia has led to CRRT circuit clot...
https://doi.org/10.1016/j.ejim.2023.02.019
European Journal of Internal Medicine; Pontremoli R, Desideri G et. al.
Mar 12th, 2023 - This analysis investigated the role of hypertriglyceridemia on renal function decline and development of end-stage kidney disease (ESKD) in a real-world clinical setting. A retrospective analysis using administrative databases of 3 Italian Local H...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10002361
International Journal of Environmental Research and Publi... Sotelo-González AM, Reynoso-Camacho R et. al.
Mar 12th, 2023 - There is an increasing interest in developing natural herb-infused functional beverages with health benefits; therefore, in this study, we aimed to evaluate the effect of strawberry, blueberry, and strawberry-blueberry blend decoction-based functi...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9997001
BMC Endocrine Disorders; Hizomi Arani R, Fakhri F et. al.
Mar 10th, 2023 - PURPOSE: This study intended to investigate the prevalence of anemia and its associated factors among patients with type 2 diabetes mellitus (T2DM) in Gorgan, Iran. This cross-sectional study was conducted on 415 (109 men) patients with T2DM refer...
Guidelines 4 results
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9019936
Orphanet Journal of Rare Diseases; Mosbah H, Donadille B et. al.
Apr 21st, 2022 - Dunnigan syndrome, or Familial Partial Lipodystrophy type 2 (FPLD2; ORPHA 2348), is a rare autosomal dominant disorder due to pathogenic variants of the LMNA gene. The objective of the French National Diagnosis and Care Protocol (PNDS; Protocole N...
https://doi.org/10.1016/j.jacc.2021.06.011
Journal of the American College of Cardiology; Virani SS, Morris PB et. al.
Aug 2nd, 2021 - 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia: A Report of the American College of Cardiology Solution Set Oversight Committee.|2021|Virani SS,Morris PB,Agarwa...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985771
Current Oncology (Toronto, Ont.); Blais N, Adam JP et. al.
Jan 4th, 2021 - The use of lorlatinib, an anaplastic lymphoma kinase (ALK) inhibitor for the treatment of ALK-positive metastatic non-small cell lung cancer, is associated with dyslipidemia in over 80% of patients. Clinical trial protocols for the management of l...
https://doi.org/10.1016/j.maturitas.2020.03.007
Maturitas Anagnostis P, Bitzer J et. al.
Mar 27th, 2020 - Dyslipidemias are common and increase the risk of cardiovascular disease. The menopause transition is associated with an atherogenic lipid profile, with an increase in the concentrations of total cholesterol (TC) and low-density lipoprotein choles...
Drugs 961 results see all →
Clinicaltrials.gov 277 results
https://clinicaltrials.gov/ct2/show/NCT05753267
Mar 9th, 2023 - Ulcerative colitis (UC) is an idiopathic, chronic inflammatory disease characterized by diffused inflammation of the colon and rectum mucosa, however the exact underlying mechanisms of UC remain poorly understood. UC is strongly dependent on cellu...
https://clinicaltrials.gov/ct2/show/NCT05609825
Mar 6th, 2023 - The main purpose of this study is to determine the tolerability and side effects related to LY3875383 given as a single injection under the skin to healthy participants and participants with elevated triglyceride (TG) levels.The study will also as...
https://clinicaltrials.gov/ct2/show/NCT01120249
Mar 2nd, 2023 - OBJECTIVES: Primary to compare recurrence-free survival in renal carcinoma patients randomly assigned to 54 weeks of everolimus versus 54 weeks of placebo after nephrectomy or partial nephrectomy. Secondary To compare the overall survival of patie...
https://clinicaltrials.gov/ct2/show/NCT05610280
Mar 1st, 2023 - This is a Phase 3, multi-center, placebo-controlled study of up to 1312 participants with hypertriglyceridemia and atherosclerotic cardiovascular disease. The study consists of 3 periods: 1) Screening Period: Week -8 to Week -1 (up to 8 weeks); 2)...
https://clinicaltrials.gov/ct2/show/NCT04562467
Mar 1st, 2023 - The development and natural history of atherothrombosis involves the pathophysiological interplay between inflammation, dyslipidemia, oxidative stress and endothelial dysfunction. Unregulated, these processes culminate in endothelial dysfunction, ...
News 276 results
https://www.medpagetoday.com/infectiousdisease/covid19/102487
Jan 3rd, 2023 - An oral remdesivir analogue (VV116) was just as good as nirmatrelvir-ritonavir (Paxlovid) for the treatment of mild-to-moderate COVID-19 in adults at risk for severe disease, and may be safer, results of a phase III trial from China suggested. Sus...
https://www.mdedge.com/rheumatology/article/260163/gout/metabolic-syndrome-may-promote-gout-young-men
Heidi Splete
Dec 15th, 2022 - Metabolic syndrome is associated with a significantly increased risk for gout in young men, but the risk can be mitigated by improvement in individual components of the syndrome, based on data from a pair of population-based studies totaling more.
https://www.mdedge.com/cardiology/article/259219/lipid-disorders/triglyceride-lowering-fails-show-cv-benefit-large-fibrate
Ted Bosworth
Nov 5th, 2022 - CHICAGO – Despite a 25% reduction in triglycerides (TGs) along with similar reductions in very-low-density lipoprotein (VLDL), and remnant cholesterol, a novel agent failed to provide any protection in a multinational trial against a composite end.
https://www.medscape.com/viewarticle/983610
Nov 5th, 2022 - Despite a 25% reduction in triglycerides (TGs) along with similar reductions in very-low-density lipoprotein (VLDL), and remnant cholesterol, a novel agent failed to provide any protection in a multinational trial against a composite endpoint of m...
https://www.onclive.com/view/pyrotinib-plus-trastuzumab-docetaxel-prolongs-pfs-in-her2-metastatic-breast-cancer
Oct 14th, 2022 - The addition of pyrotinib to trastuzumab (Herceptin) and docetaxel significantly improved progression-free survival (PFS) vs trastuzumab/docetaxel alone in patients with HER2-positive metastatic breast cancer, according to data from the phase 3 PH...